Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more
Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.00 Billion CNY
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has total liabilities worth CN¥1.00 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Nhwa Pharmaceutical Co Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inter Parfums Inc
NASDAQ:IPAR
|
USA | $460.15 Million |
|
nCino Inc
NASDAQ:NCNO
|
USA | $507.25 Million |
|
Anhui Great Wall Military Industry Co Ltd
SHG:601606
|
China | CN¥2.20 Billion |
|
Guangdong Dongfang Precision Science & Technology Co Ltd
SHE:002611
|
China | CN¥2.88 Billion |
|
Voltronic Power Technology Corp
TW:6409
|
Taiwan | NT$7.46 Billion |
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
USA | $176.95 Million |
|
Zhejiang Dingli Mach Co Ltd
SHG:603338
|
China | CN¥5.93 Billion |
|
Skyward Specialty Insurance Group, Inc. Common Stock
NASDAQ:SKWD
|
USA | $3.63 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Nhwa Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2024)
The table below shows the annual total liabilities of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.17 Billion | +27.06% |
| 2023-12-31 | CN¥918.09 Million | +2.35% |
| 2022-12-31 | CN¥896.99 Million | +13.05% |
| 2021-12-31 | CN¥793.45 Million | +23.41% |
| 2020-12-31 | CN¥642.94 Million | +7.75% |
| 2019-12-31 | CN¥596.68 Million | -44.48% |
| 2018-12-31 | CN¥1.07 Billion | +27.90% |
| 2017-12-31 | CN¥840.24 Million | -1.26% |
| 2016-12-31 | CN¥850.97 Million | +17.60% |
| 2015-12-31 | CN¥723.60 Million | -16.21% |
| 2014-12-31 | CN¥863.61 Million | +18.28% |
| 2013-12-31 | CN¥730.13 Million | +10.22% |
| 2012-12-31 | CN¥662.41 Million | +23.22% |
| 2011-12-31 | CN¥537.59 Million | +9.32% |
| 2010-12-31 | CN¥491.74 Million | +27.83% |
| 2009-12-31 | CN¥384.68 Million | -0.25% |
| 2008-12-31 | CN¥385.66 Million | -13.22% |
| 2007-12-31 | CN¥444.39 Million | +16.44% |
| 2006-12-31 | CN¥381.63 Million | +6.86% |
| 2005-12-31 | CN¥357.12 Million | -- |